5225 Results

People

  1. Giralt
    Giralt
  2. Hellmann
    Hellmann
  3. Ladanyi
    Ladanyi
  4. Motzer
    Motzer
  5. Lee
    Lee
  6. Arcila
    Arcila
  7. Berger
    Berger
  8. Hyman
    Hyman
  9. Drilon
    Drilon
  10. Levine
    Levine

Groups

  1. Department of Medicine (2296)
  2. Solid Tumor Oncology Division (1378)
  3. GSK Faculty (1136)
  4. Sloan Kettering Institute Postdocs (1044)
  5. Surgery (870)
  6. Center for Hematologic Malignancies (863)
  7. Survivorship Research (854)
  8. Hematologic Malignancies, Division of (789)
  9. Population Sciences Research Program (691)
  10. Department of Pathology and Laboratory Medicine (685)
  1. "2018"
Formats
  1. Journal Article (3011)
  2. Meeting Abstract (1948)
  3. Book Section (206)
  4. Conference Paper (38)
  5. Book Whole (11)
  6. Editorial (4)
  7. Review (4)
  8. Miscellaneous (2)
  9. Correspondence (1)
Groups
  1. Department of Medicine (2296)
  2. Solid Tumor Oncology Division (1378)
  3. GSK Faculty (1136)
  4. Sloan Kettering Institute Postdocs (1044)
  5. Surgery (870)
  6. Center for Hematologic Malignancies (863)

More Groups

People
  1. Sergio Giralt (87)
  2. Matthew Hellmann (78)
  3. Jedd Wolchok (74)
  4. Marc Ladanyi (74)
  5. Robert Motzer (71)
  6. Nancy Lee (64)

More People

Years
  1. 2018 (5225)
Publications
  1. Journal of Clinical Oncology (562)
  2. Blood (249)
  3. Cancer Research (183)
  4. Annals of Oncology (140)
  5. International Journal of Radiation Oncology, Biology, Physics (137)
  6. Modern Pathology (127)

More Publications

Publishers
  1. Elsevier Inc. (691)
  2. American Society of Clinical Oncology (605)
  3. Springer (410)
  4. American Association for Cancer Research (299)
  5. Oxford University Press (291)
  6. American Society of Hematology (273)

More Publishers

Results (5225)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study
    Meeting Abstract

    Fanale, M. A.; Hamlin, P. A.; Park, S. I.; Persky, D. O.; Higgins, J. P.; Burnett, C.; Dabovic, K.; Poma, E.; Sarapa, N.; Younes, A.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced solid tumors from a phase 1 study
    Meeting Abstract

    Fan, B.; Mellinghoff, I. K.; Wen, P. Y.; Pandya, S. S.; Jiang, L.; Liu, G.; Nimkar, T.; Yang, H.; Dai, D.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Prognostication of older Hodgkin lymphoma (HL) patients (pts): Findings from a multicenter phase II study
    Meeting Abstract

    Evens, A. M.; Advani, R. H.; Fanale, M. A.; Smith, S. M.; Helenowski, I. B.; Bociek, G.; Klein, A. K.; Winter, J. N.; Gordon, L. I.; Hamlin, P. A.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Escudier, B.; Motzer, R. J.; Rini, B. I.; Powles, T.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Gurney, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Quantitative multiplex immune fluorescence to reveal the impact of chemoradiation therapy on modulation of the immune micro-environment of pancreatic ductal adenocarcinoma
    Meeting Abstract

    Enzler, T.; Gartrell, R. D.; Fazlollahi, L.; Remotti, H. E.; Hart, T. D.; Marks, D. K.; Raufi, A.; Lu, Y.; Perni, S.; Kim, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S)
    Meeting Abstract

    El Dika, I. H.; Capanu, M.; Chou, J. F.; Harding, J. J.; Hrabovsky, A. D.; Do, R. K. G.; Shia, J.; Germino, J.; O'Reilly, E. M.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1)
    Meeting Abstract

    Drilon, A. E.; Ou, S. H. I.; Cho, B. C.; Kim, D. W.; Lee, J.; Lin, J. J.; Zhu, V. W.; Kim, H.; Kim, T. M.; Ahn, M. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia
    Meeting Abstract

    Dimopoulos, M. A.; Tedeschi, A.; Trotman, J.; Garcia-Sanz, R.; MacDonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Tam, C.; Palomba, M. L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Doebele, R. C.; Riely, G. J.; Spira, A. I.; Horn, L.; Piotrowska, Z.; Costa, D. B.; Neal, J. W.; Zhang, S.; Reichmann, W.; Kerstein, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors
    Meeting Abstract

    Desai, A. V.; Brodeur, G. M.; Foster, J.; Berg, S. L.; Basu, E. M.; Shusterman, S.; Sabnis, A. J.; Macy, M.; Yoon, J.; Gauvain, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save